Literature DB >> 22263043

Patient selection in non-small cell lung cancer: Histologic versus molecular subtypes?

Tianhong Li1.   

Abstract

Entities:  

Year:  2010        PMID： 22263043      PMCID： PMC3256471          DOI： 10.3978/j.issn.2072-1439.2010.11.9

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  25 in total

Review 1.  The new World Health Organization classification of lung tumours.

Authors:  E Brambilla; W D Travis; T V Colby; B Corrin; Y Shimosato
Journal:  Eur Respir J       Date:  2001-12       Impact factor: 16.671

2.  Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer.

Authors:  Giorgio Scagliotti; Silvia Novello; Joachim von Pawel; Martin Reck; José Rodrigues Pereira; Michael Thomas; José Elias Abrão Miziara; Beatrix Balint; Filippo De Marinis; Alan Keller; Osvaldo Arén; Maria Csollak; Istvan Albert; Carlos Henrique Barrios; Francesco Grossi; Maciej Krzakowski; Lisa Cupit; Frank Cihon; Sandra Dimatteo; Nasser Hanna
Journal:  J Clin Oncol       Date:  2010-03-08       Impact factor: 44.544

Review 3.  ASA404: a tumor vascular-disrupting agent with broad potential for cancer therapy.

Authors:  Bruce C Baguley; Mark J McKeage
Journal:  Future Oncol       Date:  2010-10       Impact factor: 3.404

4.  Outcomes of patients with advanced non-small cell lung cancer treated with gefitinib (ZD1839, "Iressa") on an expanded access study.

Authors:  Pasi A Jänne; Sarada Gurubhagavatula; Beow Y Yeap; Joan Lucca; Patricia Ostler; Arthur T Skarin; Panos Fidias; Thomas J Lynch; Bruce E Johnson
Journal:  Lung Cancer       Date:  2004-05       Impact factor: 5.705

5.  Phase II study of ASA404 (vadimezan, 5,6-dimethylxanthenone-4-acetic acid/DMXAA) 1800mg/m(2) combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer.

Authors:  Mark J McKeage; Martin Reck; Michael B Jameson; Mark A Rosenthal; David Gibbs; Paul N Mainwaring; Lutz Freitag; Richard Sullivan; Joachim Von Pawel
Journal:  Lung Cancer       Date:  2009-05-05       Impact factor: 5.705

Review 6.  Lung cancer in never smokers: molecular profiles and therapeutic implications.

Authors:  Charles M Rudin; Erika Avila-Tang; Curtis C Harris; James G Herman; Fred R Hirsch; William Pao; Ann G Schwartz; Kirsi H Vahakangas; Jonathan M Samet
Journal:  Clin Cancer Res       Date:  2009-09-15       Impact factor: 12.531

7.  Prognostic and predictive factors in a randomized phase III trial comparing cisplatin-pemetrexed versus cisplatin-gemcitabine in advanced non-small-cell lung cancer.

Authors:  K N Syrigos; J Vansteenkiste; P Parikh; J von Pawel; C Manegold; R G Martins; L Simms; K P Sugarman; C Visseren-Grul; G V Scagliotti
Journal:  Ann Oncol       Date:  2009-10-14       Impact factor: 32.976

8.  Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer.

Authors:  Giorgio Vittorio Scagliotti; Purvish Parikh; Joachim von Pawel; Bonne Biesma; Johan Vansteenkiste; Christian Manegold; Piotr Serwatowski; Ulrich Gatzemeier; Raghunadharao Digumarti; Mauro Zukin; Jin S Lee; Anders Mellemgaard; Keunchil Park; Shehkar Patil; Janusz Rolski; Tuncay Goksel; Filippo de Marinis; Lorinda Simms; Katherine P Sugarman; David Gandara
Journal:  J Clin Oncol       Date:  2008-05-27       Impact factor: 44.544

9.  Lung adenocarcinoma: modification of the 2004 WHO mixed subtype to include the major histologic subtype suggests correlations between papillary and micropapillary adenocarcinoma subtypes, EGFR mutations and gene expression analysis.

Authors:  Noriko Motoi; Janos Szoke; Gregory J Riely; Venkatraman E Seshan; Mark G Kris; Valerie W Rusch; William L Gerald; William D Travis
Journal:  Am J Surg Pathol       Date:  2008-06       Impact factor: 6.394

10.  Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer.

Authors:  David H Johnson; Louis Fehrenbacher; William F Novotny; Roy S Herbst; John J Nemunaitis; David M Jablons; Corey J Langer; Russell F DeVore; Jacques Gaudreault; Lisa A Damico; Eric Holmgren; Fairooz Kabbinavar
Journal:  J Clin Oncol       Date:  2004-06-01       Impact factor: 44.544
View more
  1 in total

1.  Glycoproteomic Approach Identifies KRAS as a Positive Regulator of CREG1 in Non-small Cell Lung Cancer Cells.

Authors:  David J Clark; Yuping Mei; Shisheng Sun; Hui Zhang; Austin J Yang; Li Mao
Journal:  Theranostics       Date:  2016-01-01       Impact factor: 11.556
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.